Loading...

Michael Evans, PhD

Title(s)Associate Professor, Radiology
SchoolSchool of Medicine
Address600 16th St
San Francisco CA 94158
Phone415-514-1292
ORCID ORCID Icon0000-0003-4947-1316 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Saint Mary's College of MarylandBA2001Chemistry
    The Scripps Research InstitutePhD2007Chemistry
    Memorial Sloan Kettering Cancer CenterPostdoctoral2013Human Oncology and Pathogenesis Program
    Collapse Awards and Honors
    The Academy for Radiology and Biomedical Imaging Research2020Distinguished Investigator Award
    The LAM Foundation2019  - 2020Pilot Award
    American Cancer Society2017  - 2021Research Scholar Award
    American Brain Tumor Association2017  - 2018Discovery Award
    UCSF2016  - 2018Brain Tumor SPORE Developmental Research Project
    UCSF Academic Senate2016  - 2017Team Science Award
    Helen Diller Family Comprehensive Cancer Center2016  - 2017Precision Imaging of Cancer and Therapy Pilot Award
    DOD Prostate Cancer Research Program2015  - 2017Idea Development Award
    UCSF Academic Senate2014  - 2015Pilot Award
    Prostate Cancer Foundation2013  - 2016David H. Koch Young Investigator Award
    National Cancer Institute2012  - 2017Pathway to Independence Award
    Imaging and Radiation Sciences Brigde Program, MSKCC2012  - 2014Research Grant
    Imaging and Radiation Sciences Bridge Program, Memorial Sloan Kettering Cancer Center2011Research Award
    Brain Tumor Center of Memorial Sloan Kettering Cancer Center2011Research Award
    National Institutes of Health and Memorial Sloan Kettering Cancer Center2007  - 2010R25 Fellowship

    Collapse Overview 
    Collapse Overview
    Michael Evans, PhD, is an Associate Professor in Residence in the UCSF Department of Radiology and Biomedical Imaging. He is a chemical biologist with an interest in biomarker discovery with proteomics, nuclear medicine, theranostics, and molecular imaging. Dr. Evans earned a BA in Chemistry from St. Mary’s College of Maryland and he obtained his PhD in Organic Chemistry from The Scripps Research Institute (CA) under the supervision of Professor Benjamin Cravatt. This was followed by a postdoctoral fellowship in Molecular Imaging from the Memorial Sloan Kettering Cancer Center in New York under the supervision of Professors Charles Sawyers and Jason Lewis. In 2013, Dr. Evans accepted a faculty position at UCSF.

    Dr. Evans is a member of the American Chemical Society, the American Association for Cancer Research, the Society of Nuclear Medicine and Molecular Imaging, and the World Molecular Imaging Society. He has been invited nationally and internationally to lecture about his research. Dr. Evans has published over 60 peer-reviewed articles, 40 meeting abstracts, and is a co-inventor on 5 patents. Dr. Evans also is the principle investigator or co-investigator on six human trials focused on new strategies for imaging solid tumors. Dr. Evans was a scientific co-founder and previously served on the scientific advisory board of ORIC Pharmaceuticals, Inc.

    Expertise:
    Chemical Biology, Positron emission tomography, Targeted Radioligand Therapy, Organic Chemistry, Cancer Biology,

    Education and Training:
    • Bachelor of Art: St. Mary’s College, St. Mary’s City, Maryland - Chemistry
    • Doctor of Philosophy: The Scripps Research Institute, La Jolla, California - Organic Chemistry
    • Postdoctoral Fellowship: Memorial Sloan Kettering Cancer Center, New York - Molecular Imaging

    Collapse Research 
    Collapse Research Activities and Funding
    Detection of the glucocorticoid receptor with PET in treatment resistant castration resistant prostate cancer
    Department of Defense Prostate Cancer Research Program W81XWH-20-1-0354Jun 1, 2020 - May 31, 2023
    Role: Principal Investigator
    Precision Targeting of Castration-Resistant Prostate Cancer with a Novel Ferrous IronDependent Therapeutic Delivery and Tumor Imaging Strategy
    Prostate Cancer Research Program W81XWH-18-1-0763Oct 15, 2018 - Oct 14, 2021
    Role: co-Principal Investigator
    Development of a translational imaging tool as a predictive biomarker for anti-PD-1/PD-L1 immunotherapies
    NIH/NIBIB R01EB025207Jul 1, 2018 - Mar 31, 2022
    Role: Principal Investigator
    Development and translation of a novel radioligand to measure pathological changes in glucocorticoid receptor expression in the brain
    NIH/NIMH R01MH115043Dec 1, 2017 - Nov 30, 2020
    Role: Principal Investigator
    Developing 68Ga-citrate PET/MR to distinguish viable tumor from psuedoprogression
    American Brain Tumor Association DG1700008Jul 31, 2017 - Jun 29, 2018
    Role: PI
    Development of a biomarker for imaging mTORC1 activity with PET
    American Cancer Society 130635-RSG-17-005-01-CCEJul 1, 2017 - Jun 30, 2021
    Role: PI
    Annotating MYC status in treatment resistant metastatic castration resistant prostate cancer with Gallium-68 citrate PET
    Department of Defense Prostate Cancer Research Program W81XWH-16-1-0469Aug 30, 2016 - Aug 31, 2019
    Role: Co-I
    Development of a radioligand to measure glucocorticoid receptor expression in enzalutamide resistant prostate cancer
    Department of Defense Prostate Cancer Research Program W81XWH-15-1-0552Sep 28, 2015 - Sep 29, 2017
    Role: PI
    Noninvasive measurement of oncogenic signaling pathways with 89Zr-transferrin
    NIH/NCI R00CA172695Jan 1, 2014 - Dec 31, 2016
    Role: Principal Investigator
    Annotating Oncogene Status in Prostate Cancer with Zr-89-transferrin PET
    NIH/NCI R01CA176671Apr 1, 2013 - Mar 31, 2018
    Role: Co-Principal Investigator
    Noninvasive measurement of oncogenic signaling pathways with 89Zr-transferrin
    NIH/NCI K99CA172695Jan 3, 2013 - Dec 31, 2014
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Featured Publications
    Collapse Websites
    Collapse In The News
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. The synthesis and structural requirements for measuring glucocorticoid receptor expression in vivo with (±)-11C-YJH08 PET. J Nucl Med. 2020 Sep 04. Huang Y, Zhao N, Wang YH, Truillet C, Wei J, Parker MFL, Blecha JE, Drake CR, VanBrocklin HF, Ruiz DG, Jacobson MP, Aggarwal R, Behr SC, Flavell RR, Wilson DM, Seo Y, Evans MJ. PMID: 32887758.
      View in: PubMed   Mentions:    Fields:    
    2. An Analysis of Isoclonal Antibody Formats Suggests a Role for Measuring PD-L1 with Low Molecular Weight PET Radiotracers. Mol Imaging Biol. 2020 Aug 19. Wei J, Wang YH, Lee CY, Truillet C, Oh DY, Xu Y, Ruggero D, Flavell RR, VanBrocklin HF, Seo Y, Craik CS, Fong L, Wang CI, Evans MJ. PMID: 32813112.
      View in: PubMed   Mentions:    Fields:    
    3. Understanding Response to Immunotherapy Using Standard of Care and Experimental Imaging Approaches. Int J Radiat Oncol Biol Phys. 2020 Sep 01; 108(1):242-257. Flavell RR, Evans MJ, Villanueva-Meyer JE, Yom SS. PMID: 32585333.
      View in: PubMed   Mentions:    Fields:    
    4. Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer. Clin Cancer Res. 2020 Jul 15; 26(14):3608-3615. Moroz A, Wang YH, Sharib JM, Wei J, Zhao N, Huang Y, Chen Z, Martinko AJ, Zhuo J, Lim SA, Zhang LH, Seo Y, Carlin S, Leung KK, Collisson EA, Kirkwood KS, Wells JA, Evans MJ. PMID: 32341034.
      View in: PubMed   Mentions:    Fields:    
    5. A Novel Radioligand Reveals Tissue Specific Pharmacological Modulation of Glucocorticoid Receptor Expression with Positron Emission Tomography. ACS Chem Biol. 2020 06 19; 15(6):1381-1391. Huang Y, Zhao N, Wang YH, Truillet C, Wei J, Blecha JE, VanBrocklin HF, Seo Y, Sayeed M, Feldman BJ, Aggarwal R, Behr SC, Shao H, Wilson DM, Villanueva-Meyer JE, Gestwicki JE, Evans MJ. PMID: 32255605.
      View in: PubMed   Mentions:    Fields:    
    6. Arabinofuranose-derived positron-emission tomography radiotracers for detection of pathogenic microorganisms. J Labelled Comp Radiopharm. 2020 May 15; 63(5):231-239. Kalita M, Parker MFL, Luu JM, Stewart MN, Blecha JE, VanBrocklin HF, Evans MJ, Flavell RR, Rosenberg OS, Ohliger MA, Wilson DM. PMID: 32222086.
      View in: PubMed   Mentions:    Fields:    
    7. Quantitative and Qualitative Improvement of Low-Count [68Ga]Citrate and [90Y]Microspheres PET Image Reconstructions Using Block Sequential Regularized Expectation Maximization Algorithm. Mol Imaging Biol. 2020 02; 22(1):208-216. Seo Y, Khalighi MM, Wangerin KA, Deller TW, Wang YH, Jivan S, Kohi MP, Aggarwal R, Flavell RR, Behr SC, Evans MJ. PMID: 30993558.
      View in: PubMed   Mentions:    Fields:    
    8. Profiling the Surfaceome Identifies Therapeutic Targets for Cells with Hyperactive mTORC1 Signaling. Mol Cell Proteomics. 2020 02; 19(2):294-307. Wei J, Leung K, Truillet C, Ruggero D, Wells JA, Evans MJ. PMID: 31792071.
      View in: PubMed   Mentions: 1     Fields:    
    9. Synthesis and Initial Biological Evaluation of Boron-Containing Prostate-Specific Membrane Antigen Ligands for Treatment of Prostate Cancer Using Boron Neutron Capture Therapy. Mol Pharm. 2019 09 03; 16(9):3831-3841. Wang S, Blaha C, Santos R, Huynh T, Hayes TR, Beckford-Vera DR, Blecha JE, Hong AS, Fogarty M, Hope TA, Raleigh DR, Wilson DM, Evans MJ, VanBrocklin HF, Ozawa T, Flavell RR. PMID: 31381351.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    10. Measuring Dynamic Changes in the Labile Iron Pool in Vivo with a Reactivity-Based Probe for Positron Emission Tomography. ACS Cent Sci. 2019 Apr 24; 5(4):727-736. Muir RK, Zhao N, Wei J, Wang YH, Moroz A, Huang Y, Chen YC, Sriram R, Kurhanewicz J, Ruggero D, Renslo AR, Evans MJ. PMID: 31041393.
      View in: PubMed   Mentions:
    11. Enzymatically Catalyzed Radiofluorination of Biomolecules. Methods Mol Biol. 2019; 2033:191-205. Drake CR, Evans MJ, VanBrocklin HF. PMID: 31332755.
      View in: PubMed   Mentions:    Fields:    Translation:Cells
    12. Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity. J Clin Invest. 2019 01 02; 129(1):349-363. Pai CS, Simons DM, Lu X, Evans M, Wei J, Wang YH, Chen M, Huang J, Park C, Chang A, Wang J, Westmoreland S, Beam C, Banach D, Bowley D, Dong F, Seagal J, Ritacco W, Richardson PL, Mitra S, Lynch G, Bousquet P, Mankovich J, Kingsbury G, Fong L. PMID: 30530991.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    13. Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR. JCI Insight. 2018 11 02; 3(21). Behr SC, Villanueva-Meyer JE, Li Y, Wang YH, Wei J, Moroz A, Lee JK, Hsiao JC, Gao KT, Ma W, Cha S, Wilson DM, Seo Y, Nelson SJ, Chang SM, Evans MJ. PMID: 30385712.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    14. A Preclinical Assessment of 89Zr-atezolizumab Identifies a Requirement for Carrier Added Formulations Not Observed with 89Zr-C4. Bioconjug Chem. 2018 10 17; 29(10):3476-3482. Moroz A, Lee CY, Wang YH, Hsiao JC, Sevillano N, Truillet C, Craik CS, Fong L, Wang CI, Evans MJ. PMID: 30227708.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    15. AGuIX® from bench to bedside-Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine. Br J Radiol. 2019 Jan; 92(1093):20180365. Lux F, Tran VL, Thomas E, Dufort S, Rossetti F, Martini M, Truillet C, Doussineau T, Bort G, Denat F, Boschetti F, Angelovski G, Detappe A, Crémillieux Y, Mignet N, Doan BT, Larrat B, Meriaux S, Barbier E, Roux S, Fries P, Müller A, Abadjian MC, Anderson C, Canet-Soulas E, Bouziotis P, Barberi-Heyob M, Frochot C, Verry C, Balosso J, Evans M, Sidi-Boumedine J, Janier M, Butterworth K, McMahon S, Prise K, Aloy MT, Ardail D, Rodriguez-Lafrasse C, Porcel E, Lacombe S, Berbeco R, Allouch A, Perfettini JL, Chargari C, Deutsch E, Le Duc G, Tillement O. PMID: 30226413.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimals
    16. A PET Imaging Strategy for Interrogating Target Engagement and Oncogene Status in Pancreatic Cancer. Clin Cancer Res. 2019 01 01; 25(1):166-176. Henry KE, Dacek MM, Dilling TR, Caen JD, Fox IL, Evans MJ, Lewis JS. PMID: 30228208.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    17. Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. Eur J Nucl Med Mol Imaging. 2018 11; 45(12):2045-2054. Afshar-Oromieh A, Debus N, Uhrig M, Hope TA, Evans MJ, Holland-Letz T, Giesel FL, Kopka K, Hadaschik B, Kratochwil C, Haberkorn U. PMID: 29980832.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    18. Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer. Eur Urol Oncol. 2018 05; 1(1):78-82. Aggarwal R, Wei X, Kim W, Small EJ, Ryan CJ, Carroll P, Cooperberg M, Evans MJ, Hope T. PMID: 31100231.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    19. Development of a stress response therapy targeting aggressive prostate cancer. Sci Transl Med. 2018 05 02; 10(439). Nguyen HG, Conn CS, Kye Y, Xue L, Forester CM, Cowan JE, Hsieh AC, Cunningham JT, Truillet C, Tameire F, Evans MJ, Evans CP, Yang JC, Hann B, Koumenis C, Walter P, Carroll PR, Ruggero D. PMID: 29720449.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    20. PET imaging of tumor PD-L1 expression with 89Zr-labeled anti-PD-L1 antibodies. Nuklearmedizin. 2018 May 1; 42(3):158. C. Truillet, N. Sevillano, B. Jego, E. Jaumain, C. Craik, C.I. Wang, M. Evans. .
      View in: Publisher Site   Mentions:
    21. Measuring glucocorticoid receptor expression in vivo with PET. Oncotarget. 2018 Apr 17; 9(29):20399-20408. Truillet C, Parker MFL, Huynh LT, Wei J, Jami KM, Wang YH, Shen YS, Sriram R, Wilson DM, Kurhanewicz J, Evans MJ. PMID: 29755660.
      View in: PubMed   Mentions:    Fields:    
    22. Targeting RAS-driven human cancer cells with antibodies to upregulated and essential cell-surface proteins. Elife. 2018 01 23; 7. Martinko AJ, Truillet C, Julien O, Diaz JE, Horlbeck MA, Whiteley G, Blonder J, Weissman JS, Bandyopadhyay S, Evans MJ, Wells JA. PMID: 29359686.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    23. Imaging PD-L1 Expression with ImmunoPET. Bioconjug Chem. 2018 01 17; 29(1):96-103. Truillet C, Oh HLJ, Yeo SP, Lee CY, Huynh LT, Wei J, Parker MFL, Blakely C, Sevillano N, Wang YH, Shen YS, Olivas V, Jami KM, Moroz A, Jego B, Jaumain E, Fong L, Craik CS, Chang AJ, Bivona TG, Wang CI, Evans MJ. PMID: 29125731.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    24. Development of 5N-Bicalutamide, a High-Affinity Reversible Covalent Antiandrogen. ACS Chem Biol. 2017 12 15; 12(12):2934-2939. de Jesus Cortez F, Nguyen P, Truillet C, Tian B, Kuchenbecker KM, Evans MJ, Webb P, Jacobson MP, Fletterick RJ, England PM. PMID: 28981251.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    25. Metabolic reprogramming ensures cancer cell survival despite oncogenic signaling blockade. Genes Dev. 2017 10 15; 31(20):2067-2084. Lue HW, Podolak J, Kolahi K, Cheng L, Rao S, Garg D, Xue CH, Rantala JK, Tyner JW, Thornburg KL, Martinez-Acevedo A, Liu JJ, Amling CL, Truillet C, Louie SM, Anderson KE, Evans MJ, O'Donnell VB, Nomura DK, Drake JM, Ritz A, Thomas GV. PMID: 29138276.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    26. Noninvasive 89Zr-Transferrin PET Shows Improved Tumor Targeting Compared with 18F-FDG PET in MYC-Overexpressing Human Triple-Negative Breast Cancer. J Nucl Med. 2018 01; 59(1):51-57. Henry KE, Dilling TR, Abdel-Atti D, Edwards KJ, Evans MJ, Lewis JS. PMID: 28848040.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    27. Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer. Mol Cancer Res. 2017 09; 15(9):1221-1229. Aggarwal R, Behr SC, Paris PL, Truillet C, Parker MFL, Huynh LT, Wei J, Hann B, Youngren J, Huang J, Premasekharan G, Ranatunga N, Chang E, Gao KT, Ryan CJ, Small EJ, Evans MJ. PMID: 28592703.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    28. Imaging Hepatocellular Carcinoma With 68Ga-Citrate PET: First Clinical Experience. Mol Imaging. 2017 Jan-Dec; 16:1536012117723256. Mari Aparici C, Behr SC, Seo Y, Kelley RK, Corvera C, Gao KT, Aggarwal R, Evans MJ. PMID: 28893116.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    29. Noninvasive Measurement of mTORC1 Signaling with 89Zr-Transferrin. Clin Cancer Res. 2017 Jun 15; 23(12):3045-3052. Truillet C, Cunningham JT, Parker MFL, Huynh LT, Conn CS, Ruggero D, Lewis JS, Evans MJ. PMID: 28007777.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    30. A Feasibility Study Showing [68Ga]Citrate PET Detects Prostate Cancer. Mol Imaging Biol. 2016 12; 18(6):946-951. Behr SC, Aggarwal R, Seo Y, Aparici CM, Chang E, Gao KT, Tao DH, Small EJ, Evans MJ. PMID: 27184068.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    31. 68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience. J Nucl Med. 2017 Jan; 58(1):81-84. Hope TA, Truillet C, Ehman EC, Afshar-Oromieh A, Aggarwal R, Ryan CJ, Carroll PR, Small EJ, Evans MJ. PMID: 27660139.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansAnimalsCells
    32. Synthesis and Characterization of (89)Zr-Labeled Ultrasmall Nanoparticles. Mol Pharm. 2016 07 05; 13(7):2596-601. Truillet C, Thomas E, Lux F, Huynh LT, Tillement O, Evans MJ. PMID: 27266800.
      View in: PubMed   Mentions: 4     Fields:    Translation:Animals
    33. A reactivity-based [18F]FDG probe for in vivo formaldehyde imaging using positron emission tomography. Chem Sci. 2016 Aug 01; 7(8):5503-5507. Liu W, Truillet C, Flavell RR, Brewer TF, Evans MJ, Wilson DM, Chang CJ. PMID: 30034690.
      View in: PubMed   Mentions:
    34. Site-Specific Radiofluorination of Biomolecules with 8-[(18)F]-Fluorooctanoic Acid Catalyzed by Lipoic Acid Ligase. ACS Chem Biol. 2016 06 17; 11(6):1587-94. Drake CR, Sevillano N, Truillet C, Craik CS, VanBrocklin HF, Evans MJ. PMID: 27008570.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    35. [(11)C]Ascorbic and [(11)C]dehydroascorbic acid, an endogenous redox pair for sensing reactive oxygen species using positron emission tomography. Chem Commun (Camb). 2016 Apr 07; 52(27):4888-90. Carroll VN, Truillet C, Shen B, Flavell RR, Shao X, Evans MJ, VanBrocklin HF, Scott PJ, Chin FT, Wilson DM. PMID: 26963495.
      View in: PubMed   Mentions: 8     Fields:    Translation:Cells
    36. A Reactivity-Based [18F]FDG Probe for In Vivo Formaldehyde Imaging Using Positron Emission Tomography. Chemical Science. 2016; (7):5503-5507. Liu, W.; Truillet, C.; Flavell, R.R.; Brewer, T.; Evans, M.J.; Wilson, D.M.; Chang, C.
    37. 11C-Ascorbic and 11C-dehydroascorbic acid, an endogenous redox pair for sensing reactive oxygen species using positron emission tomography. Chemical Communications. 2016; 27(52):4888-4890. Carroll, V.N.; Truillet, C.; Shen, B.; Flavell, R.R.; Shao, X.; Evans, M.J.; VanBrocklin, H.F.; Scott, P.H.J.; Chin, F.T.; Wilson, D.M.
    38. Applying 8?Zr-Transferrin To Study the Pharmacology of Inhibitors to BET Bromodomain Containing Proteins. Mol Pharm. 2016 Feb 01; 13(2):683-8. Doran MG, Carnazza KE, Steckler JM, Spratt DE, Truillet C, Wongvipat J, Sawyers CL, Lewis JS, Evans MJ. PMID: 26725682.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimals
    39. Caged [(18)F]FDG Glycosylamines for Imaging Acidic Tumor Microenvironments Using Positron Emission Tomography. Bioconjug Chem. 2016 Jan 20; 27(1):170-8. Flavell RR, Truillet C, Regan MK, Ganguly T, Blecha JE, Kurhanewicz J, VanBrocklin HF, Keshari KR, Chang CJ, Evans MJ, Wilson DM. PMID: 26649808.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    40. Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation. Cancer Res. 2015 Nov 15; 75(22):4688-96. Spratt DE, Evans MJ, Davis BJ, Doran MG, Lee MX, Shah N, Wongvipat J, Carnazza KE, Klee GG, Polkinghorn W, Tindall DJ, Lewis JS, Sawyers CL. PMID: 26432404.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansAnimalsCells
    41. Anthropometric Measures at Multiple Times Throughout Life and Prostate Cancer Diagnosis, Metastasis, and Death. Eur Urol. 2015 Dec; 68(6):1076-82. Gerdtsson A, Poon JB, Thorek DL, Mucci LA, Evans MJ, Scardino P, Abrahamsson PA, Nilsson P, Manjer J, Bjartell A, Malm J, Vickers A, Freedland SJ, Lilja H, Ulmert D. PMID: 25794458.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    42. Annotating STEAP1 regulation in prostate cancer with 89Zr immuno-PET. J Nucl Med. 2014 Dec; 55(12):2045-9. Doran MG, Watson PA, Cheal SM, Spratt DE, Wongvipat J, Steckler JM, Carrasquillo JA, Evans MJ, Lewis JS. PMID: 25453051.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    43. Cabozantinib Resolves Bone Scans in Tumor-Naïve Mice Harboring Skeletal Injuries. Mol Imaging. 2014 Oct 01; 13(8):7290201400026. Doran MG, Spratt DE, Wongvipat J, Ulmert D, Carver BS, Sawyers CL, Evans MJ. PMID: 28650280.
      View in: PubMed   Mentions:
    44. 89Zr-MSTP2109A, A Novel Antibody Based Radiotracer to Evaluate and Guide the Clinical Translation of Antibody-Drug Conjugates Targeting STEAP1. International Journal of Radiation Oncology • Biology • Physics. 2014 Sep 1; 90(1):s791. D.E. Spratt, M.G. Doran, J. Wongvipat, J.S. Lewis, M.J. Evans. .
      View in: Publisher Site   Mentions:
    45. CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. Genes Dev. 2014 Aug 15; 28(16):1800-14. Huang CH, Lujambio A, Zuber J, Tschaharganeh DF, Doran MG, Evans MJ, Kitzing T, Zhu N, de Stanchina E, Sawyers CL, Armstrong SA, Lewis JS, Sherr CJ, Lowe SW. PMID: 25128497.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansAnimalsCells
    46. Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2014 May; 41(5):985-94. Cheal SM, Punzalan B, Doran MG, Evans MJ, Osborne JR, Lewis JS, Zanzonico P, Larson SM. PMID: 24604591.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    47. Cabozantinib resolves bone scans in tumor-naïve mice harboring skeletal injuries. Mol Imaging. 2014; 13. Doran MG, Spratt DE, Wongvipat J, Ulmert D, Carver BS, Sawyers CL, Evans MJ. PMID: 25248353.
      View in: PubMed   Mentions: 3     Fields:    Translation:Animals
    48. Underscoring the influence of inorganic chemistry on nuclear imaging with radiometals. Inorg Chem. 2014 Feb 17; 53(4):1880-99. Zeglis BM, Houghton JL, Evans MJ, Viola-Villegas N, Lewis JS. PMID: 24313747.
      View in: PubMed   Mentions: 20     Fields:    Translation:Animals
    49. Applying PET to broaden the diagnostic utility of the clinically validated CA19.9 serum biomarker for oncology. J Nucl Med. 2013 Nov; 54(11):1876-82. Viola-Villegas NT, Rice SL, Carlin S, Wu X, Evans MJ, Sevak KK, Drobjnak M, Ragupathi G, Sawada R, Scholz WW, Livingston PO, Lewis JS. PMID: 24029655.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimalsCells
    50. Prostate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. Established relevance and emerging roles. Thromb Haemost. 2013 Sep; 110(3):484-92. Thorek DL, Evans MJ, Carlsson SV, Ulmert D, Lilja H. PMID: 23903407.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    51. Overcoming mutation-based resistance to antiandrogens with rational drug design. Elife. 2013 Apr 09; 2:e00499. Balbas MD, Evans MJ, Hosfield DJ, Wongvipat J, Arora VK, Watson PA, Chen Y, Greene GL, Shen Y, Sawyers CL. PMID: 23580326.
      View in: PubMed   Mentions: 121     Fields:    Translation:HumansCells
    52. Imaging of tumor vascularization using fluorescence molecular tomography to monitor arginine deiminase treatment in melanoma. Mol Imaging. 2013 Jan-Feb; 12(1):67-73. Stelter L, Evans MJ, Jungbluth AA, Longo VA, Zanzonico P, Ritter G, Bomalaski JS, Old L, Larson SM. PMID: 23348793.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    53. Imaging tumor burden in the brain with 89Zr-transferrin. J Nucl Med. 2013 Jan; 54(1):90-5. Evans MJ, Holland JP, Rice SL, Doran MG, Cheal SM, Campos C, Carlin SD, Mellinghoff IK, Sawyers CL, Lewis JS. PMID: 23236019.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    54. Measuring oncogenic signaling pathways in cancer with PET: an emerging paradigm from studies in castration-resistant prostate cancer. Cancer Discov. 2012 Nov; 2(11):985-94. Evans MJ. PMID: 23043150.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    55. Annotating MYC status with 89Zr-transferrin imaging. Nat Med. 2012 Oct; 18(10):1586-91. Holland JP, Evans MJ, Rice SL, Wongvipat J, Sawyers CL, Lewis JS. PMID: 23001181.
      View in: PubMed   Mentions: 29     Fields:    Translation:Animals
    56. Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen. Cancer Discov. 2012 Apr; 2(4):320-7. Ulmert D, Evans MJ, Holland JP, Rice SL, Wongvipat J, Pettersson K, Abrahamsson PA, Scardino PT, Larson SM, Lilja H, Lewis JS, Sawyers CL. PMID: 22576209.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansAnimalsCells
    57. A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index. Eur Urol. 2012 Jul; 62(1):78-84. Ulmert D, Kaboteh R, Fox JJ, Savage C, Evans MJ, Lilja H, Abrahamsson PA, Björk T, Gerdtsson A, Bjartell A, Gjertsson P, Höglund P, Lomsky M, Ohlsson M, Richter J, Sadik M, Morris MJ, Scher HI, Sjöstrand K, Yu A, Suurküla M, Edenbrandt L, Larson SM. PMID: 22306323.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    58. Novel mechanistic insights into arginine deiminase pharmacology suggest 18F-FDG is not suitable to evaluate clinical response in melanoma. J Nucl Med. 2012 Feb; 53(2):281-6. Stelter L, Evans MJ, Jungbluth AA, Zanzonico P, Ritter G, Ku T, Rosenfeld E, Bomalaski JS, Old L, Larson SM. PMID: 22228793.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    59. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci U S A. 2011 Jun 07; 108(23):9578-82. Evans MJ, Smith-Jones PM, Wongvipat J, Navarro V, Kim S, Bander NH, Larson SM, Sawyers CL. PMID: 21606347.
      View in: PubMed   Mentions: 78     Fields:    Translation:HumansAnimalsCells
    60. The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. Proc Natl Acad Sci U S A. 2010 Apr 06; 107(14):6459-64. Vivanco I, Rohle D, Versele M, Iwanami A, Kuga D, Oldrini B, Tanaka K, Dang J, Kubek S, Palaskas N, Hsueh T, Evans M, Mulholland D, Wolle D, Rajasekaran S, Rajasekaran A, Liau LM, Cloughesy TF, Dikic I, Brennan C, Wu H, Mischel PS, Perera T, Mellinghoff IK. PMID: 20308550.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansAnimalsCells
    61. Mechanistic and structural requirements for active site labeling of phosphoglycerate mutase by spiroepoxides. Mol Biosyst. 2007 Jul; 3(7):495-506. Evans MJ, Morris GM, Wu J, Olson AJ, Sorensen EJ, Cravatt BF. PMID: 17579775.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    62. Noxious compounds activate TRPA1 ion channels through covalent modification of cysteines. Nature. 2007 Feb 01; 445(7127):541-5. Macpherson LJ, Dubin AE, Evans MJ, Marr F, Schultz PG, Cravatt BF, Patapoutian A. PMID: 17237762.
      View in: PubMed   Mentions: 382     Fields:    Translation:HumansAnimalsCells
    63. Mechanism-based profiling of enzyme families. Chem Rev. 2006 Aug; 106(8):3279-301. Evans MJ, Cravatt BF. PMID: 16895328.
      View in: PubMed   Mentions: 114     Fields:    Translation:HumansAnimalsCells
    64. Target discovery in small-molecule cell-based screens by in situ proteome reactivity profiling. Nat Biotechnol. 2005 Oct; 23(10):1303-7. Evans MJ, Saghatelian A, Sorensen EJ, Cravatt BF. PMID: 16200062.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansCells
    Michael's Networks
    Concepts (291)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (63)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _
    ↑